PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

46 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
21.
Wulfkuhle, J.D.* et al.: Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin. Cancer Res. 18, 6426-6435 (2012)
22.
Butterfield, L.H.* et al.: Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin. Cancer Res. 17, 3064-3076 (2011)
23.
Ehrhardt, H. ; Wachter, F. ; Maurer, M. ; Stahnke, K.* & Jeremias, I.: Important role of Caspase-8 for chemo-sensitivity of ALL cells. Clin. Cancer Res. 17, 7605-7613 (2011)
24.
Leisegang, M.* et al.: T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy. Clin. Cancer Res. 16, 2333-2343 (2010)
25.
Smida, J. et al.: Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin. Cancer Res. 16, 4256-4267 (2010)
26.
Reindl, C. et al.: CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin. Cancer Res. 15, 2238-2247 (2009)
27.
Miederer, M.* et al.: Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin. Cancer Res. 14, 3555-3561 (2008)
28.
Vempati, S. et al.: Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. Clin. Cancer Res. 14, 4437-4445 (2008)
29.
Lassmann, S.* et al.: Predictive value of aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin. Cancer Res. 13, 4083-4091 (2007)
30.
Napieralski, R.* et al.: Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: Relation to therapy response and clinicopathologic and molecular features. Clin. Cancer Res. 13, 5095-5102 (2007)
31.
Nößner, E. & Schleypen, J.S.*: The complexity of natural killer cells. Clin. Cancer Res. 13, S. 1621 (2007)
32.
Rauser, S. et al.: Significance of HER2 low-level copy gain in Barrett's cancer: Implications for fluorescence in situ hybridization testing in tissues. Clin. Cancer Res. 13, 5115-5123 (2007)
33.
Rokavec, M.* et al.: A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk. Clin. Cancer Res. 13, 7506-7514 (2007)
34.
Buters, J.T.M.: Effective strategies for tumors affecting chemopreventive metabolism. Clin. Cancer Res. 12, 7203-7204 (2006)
35.
Petrich, T.* et al.: Effective cancer therapy with the alpha-particle ermitter [211At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors. Clin. Cancer Res. 12, 1342-1348 (2006)
36.
Reiter, R.* et al.: Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin. Cancer Res. 12, 5136-5141 (2006)
37.
Schleypen, J.S. et al.: Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin. Cancer Res. 12, 718-725 (2006)
38.
von Luettichau, I.* et al.: Mononuclear infiltrates in osteosarcoma and chemokine receptor expression. Clin. Cancer Res. 12, 5253-5254 (2006)
39.
Frankenberger, B. et al.: Influence of CD80 Interleukin2, and Interleukin-7 Expression in Human Renal Cell Carcinoma on the Expression, Function, and Survival of Tumor-Specific CTLs. Clin. Cancer Res. 11, 1733-1742 (2005)
40.
Gangnus, R.* ; Langer, S. ; Breit, E.* ; Pantel, K.* & Speicher, M.R.: Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin. Cancer Res. 10, 3457-3464 (2004)
▮◀ ◀◀ 1 ... 2 ... 3 ... ▶▶ ▶▮